Nordic Capital subsidiary Cidron Aida Bidco has acquired all issued and to-be-issued limited voting share capital of UK-based speciality pharmaceutical company, Advanz Pharma, for a total value of nearly $846m.
According to the deal, each Advanz Pharma shareholder will get $17.26 in cash per share of the company.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This excludes Bybrook, the former shareholder of the company who opted for the alternative offer and whose shares were swapped for Topco B Shares.
Nordic Capital Advisors partner and Healthcare head Raj Shah said: “Advanz Pharma’s vision and regional focus fully aligns with Nordic Capital’s expertise and deep knowledge of European market sectors.
“Nordic Capital will help fuel the company’s strategic growth and allow it to invest in the future pipeline and M&A activities so that even more patients can access critical medicines now and in the future.”
The acquisition will offer investment and capacities to support the growth of Advanz Pharma, which focuses on complex medicines in Europe.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt could help in delivering additional cost-savings to the UK National Health Service and European healthcare systems while increasing options and global access to critical medicines.
Advanz Pharma delivers and improves the critical drugs patients depend on and facilitates sustained access while enhancing health outcomes.
Furthermore, the company’s capabilities in anti-infectives and endocrinology therapy fields and collaborations with hospital decision-makers make it an ideal partner for marketing complex treatments in Europe, Advanz Pharma noted.
Advanz Pharma CEO Graeme Duncan said: “Nordic Capital will be pivotal in helping the business through both its deep sector expertise and access to capital that will enable considerable investment in our organic and inorganic pipeline.
“This partnership will be essential in allowing us to further broaden choice for both prescribers and patients throughout the world and ensure access to the essential medicines we supply.”
The deal was executed through a court-sanctioned scheme of arrangement.
